Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management
Journal of the American Academy of Dermatology · 2026-08 · 95 (2) · 485-493
DOI: 10.1016/j.jaad.2026.02.072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Maggie H Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Vagelos College of Physicians and Surgeons, New York, New York. Hauptthemen laut MEDLINE: Dermatofibrosarcoma, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Dermatofibrosarcoma protuberans (DFSP) is a rare subcutaneous soft tissue malignancy associated with high local recurrence rates but low propensity for distant metastases, thus mandating aggressive loco-regional control. Diagnosis depends on histopathological evaluation, with CD34 staining needed for confirmation. There is no known sex predilection, however Black patients are disproportionately affected. When subclinical extension is suspected, magnetic resonance imaging or computed tomography may be performed, but are not routinely indicated. Patients with extensive tumor invasion or fibrosarcomatous DFSP, an aggressive variant associated with worse prognosis compared to DFSP, necessitate management by a multidisciplinary team including soft tissue sarcoma experts. We recommend Mohs micrographic surgery as the preferred treatment for DFSP given its comprehensive margin assessment, resulting in significantly lower local recurrence rates. Radiation therapy and imatinib may be considered for unresectable tumors, and we advise that COL1A1-PDGFB fusion is confirmed before starting imatinib. Possible therapeutic targets, including EGFR, PD-L1, and PRAME, have been identified by molecular analyses. Advances in organoid models and single-cell RNA sequencing have improved understanding of the tumor microenvironment. However, racial disparities in diagnosis and treatment emphasize the need for a high index of suspicion in skin of color patients to reduce misdiagnosis and delays in care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
- Georgetown University School of Medicine, Washington, District of Columbia.
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
- Department of Dermatology, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio.
- Department of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota.
- Department of Dermatology, Weill Cornell Medicine, New York, New York.
Zitieren
APA
Zhou, M. H., Stirrat, T. P., Alam, M., Bordeaux, J. S., Brewer, J. D., Minkis, K., Nouri, K., Remotti, F., Matushansky, I., & Lipner, S. R. (2026). Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management. Journal of the American Academy of Dermatology, 95(2), 485-493. https://doi.org/10.1016/j.jaad.2026.02.072
Vancouver
Zhou MH, Stirrat TP, Alam M, Bordeaux JS, Brewer JD, Minkis K, et al. Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management. Journal of the American Academy of Dermatology. 2026;95(2):485-493. doi:10.1016/j.jaad.2026.02.072
BibTeX
@article{Zhou2026,
author = {Zhou, Maggie H and Stirrat, Thomas P and Alam, Murad and Bordeaux, Jeremy S and Brewer, Jerry D and Minkis, Kira and Nouri, Keyvan and Remotti, Fabrizio and Matushansky, Igor and Lipner, Shari R},
title = {Dermatofibrosarcoma protuberans: A clinical review of diagnosis and management},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {2},
pages = {485--493},
doi = {10.1016/j.jaad.2026.02.072}
}
EUVIMED